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Interleukin-12 (IL-12) has been shown to possess potent immunoregulatory and antitumoral effects. We have evaluated the
anti-oncogenic potential and the mechanisms of the antitumoral effect of in vivo adenovirus-mediated transfer of IL-12 gene in a
murine model of colon cancer. AdCMVIL-12 was constructed to permit coordinated production of p40 and p35 subunits of IL-12
gene to obtain the maximum IL-12 bioactivity. Infection of murine colon cancer CT-26 cells in vitro with AdCMVIL-12 resulted in
the production of high levels of IL-12. In vivo gene therapy of colon cancer nodules by intratumoral injection of AdCMVIL-12
induced a local increase in IL-12 and interferon-g levels and a complete regression of the tumor in 26 of 34 (76%) mice. Tumor
disappeared between days 7 and 10 after vector administration. The antitumoral effect was mediated by CD81 T cells and was
associated with the generation of cytotoxic T lymphocytes against colon cancer cells. Animals that eliminated the tumor were
protected against a second administration of neoplastic cells. Treatment with AdCMVIL-12 of one tumor nodule also caused
regression of established tumors at distant sites. These data demonstrate that AdCMVIL-12 is a useful therapeutic tool for established
colon cancer in mice and should be considered for application in humans.
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Colorectal carcinoma is highly prevalent in mostWesternized countries, with an incidence that ap-
pears to rise steadily from the second to ninth decade of
life. Progression of the disease occurs through invasion
of the colonic wall, involvement of regional lymph
nodes, and distant metastasis. At the time of diagnosis,
approximately half of patients have tumors invading
through the bowel wall with spread to regional lymph
nodes; in addition, 10% of patients present with synchro-
nous metastatic cancer to the liver, which may be the
presenting manifestation of the disease.1
Surgery is associated with a 90% 5-year survival rate in
patients with tumors involving only the mucosa or
submucosa. However, in those patients with transmural
penetration, survival decreases to 60–80%;2 only ;30–
60% of patients with regional lymph node metastasis3
and ,6% of those with distant metastasis are disease
free at 5 years.4 At present there is no therapeutic
regime capable of prolonging survival in patients with
advanced colon cancer. Thus, this disease remains a
formidable therapeutic challenge.
The use of gene therapy to enhance immunological
responses against tumor cells has emerged as a promis-
ing new approach to treat cancer.5–8 Systemic treatment
with cytokines or, even better, the induction of local
production of cytokines in the proper tumor mass, can
attract and activate different types of immunocytes and
create an inflammatory response leading to tumor rejec-
tion.5–9 Among the different cytokines, interleukin-12
(IL-12) is of particular interest because of its critical role
in the stimulation of cell-mediated immunity.10 IL-12,
which is mainly produced by antigen-presenting cells,
has been shown to augment the cytotoxic activity of
natural killer and activated T cells, to induce the pro-
duction of interferon-g (IFN-g), and to promote the
differentiation of uncommitted T lymphocytes to T
helper type 1 cells.10–15
Because of its potent biological activities, IL-12 is
considered to be a promising substance in cancer immu-
notherapy.11,16 However, although systemic administra-
tion of IL-12 has been shown to be highly effective in
inducing tumor regression and reducing metastases in
diverse murine models of solid tumors,9,17–21 important
hematological, hepatotoxic, and muscular side effects
seriously limit its use as an anticancer agent.13,21,22 Thus,
although a phase I clinical trial of systemic IL-12 treat-
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ment in subjects with renal cell carcinoma showed
objective tumor responses in several patients, a subse-
quent phase II trial of IL-12 in advanced renal cell
cancer was discontinued because of severe toxicity,
including death.23,24
It seems therefore that the use of procedures allowing
high local production of IL-12 at the site of interest (the
tumor mass) without increasing systemic levels of the
cytokine would probably achieve therapeutic effects
without toxicity. To this aim, different strategies based
on the transduction of tumoral cells with IL-12 genes
have been attempted to treat various neoplasms.25–36
One of systems enabling efficient in vivo transduction
of tumoral cells is the use of adenoviral vectors. These
vectors can be produced at high titers, can transduce a
wide variety of cell types independently of cell cycle, and
can induce high levels of transgene expression.37 In the
present paper, we have used a murine model of syngenic
colon cancer to evaluate the anti-oncogenic potential of
in vivo transduction of established tumors with an ad-
enoviral vector (AdCMVIL-12) expressing high levels of
bioactive IL-12. Our results showed that intratumoral
(i.t.) administration of the vector caused regression of
the treated nodule and of distant lesions and induced
long-lasting protective immunity against tumor rechal-
lenge without any apparent toxic effect. The antitumoral
effect of the treatment was shown to be largely mediated
by CD81 T cells and was associated with the emergence
of a potent cytotoxic T-cell response against tumoral
cells. These results provide an experimental basis for
consideration of this therapy as a possible treatment for
colon cancer in humans.
MATERIALS AND METHODS
Construction of adenovirus
Recombinant adenovirus carrying IL-12 under the control of
the cytomegalovirus (CMV) promoter was constructed as
follows: A HindIII/SpeI fragment of pBS/p35 with cDNA of the
p35 subunit of IL-12 was filled in by Klenow and blunt-end
ligated into BamHI-cut pMV100, which carries the CMV
promoter and a poly(A) signal. The resultant plasmid was cut
by HindIII to release a p35 expression cassette that was ligated
into EcoRI-cut pDE1sp1A by blunt-end ligation (pDE1sp1A/
p40). A NcoI/SmaI fragment of pBS/p40 containing the p40
subunit of IL-12 was cloned into NcoI/EcoRV-cut pCITE-1
carrying internal ribosome entry site (IRES). The resultant
plasmid was cut by EcoRI to release the IRES/p40 fragment;
this fragment, in turn, was cloned into EcoRI-cut pDE1sp1A/
p40 to form pDE1sp1A/IL-12. A BamHI/SalI fragment con-
taining CMV promoter, p35, IRES p40, and poly(A) signal was
cloned into HindIII-cut adenovirus plasmid pMV60 to form
pMV60/IL-12. pMV60/IL-12 and pJM17 were cotransfected
into 293 cells, and plaques were screened to obtain AdCMVIL-
12. Adenovirus carrying lacZ reporter gene under the control
of the CMV promoter (AdCMVlacZ) was produced as de-
scribed previously.38 Recombinant adenoviruses were isolated
from a single plaque, expanded in 293 cells, and purified by
double CsCl ultracentrifugation. The purified virus was exten-
sively dialyzed against 10 mM tris(hydroxymethyl)aminometh-
ane/1 mM MgCl2 and stored in aliquots at 280°C. The virus
titer was determined by plaque assay.
Animals, cell culture, and reagents
We used 5- to 8-week-old BALB/c female mice in this study.
They were purchased from Charles River (Barcelona, Spain).
During the experimental period, animals were housed under
standard conditions according to institutional guidelines.
We obtained 293 cells (adenoviral E1-transformed human
embryonic kidney cells) from the American Type Culture
Collection (Manassas, Va). The CT-26 tumor cell line, an
undifferentiated murine colorectal adenocarcinoma cell line,39
was established from an N-nitroso-N-methylurethan-induced
transplantable tumor40 in BALB/c (H-2d) mice; this cell line
was a kind gift of Dr. K. Brand, Max-Planck-Institut fur
Biochemie (Berlin, Germany). 293 cells were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10%
heat-inactivated fetal calf sera (FCS), 2 mM L-glutamine, 100
U/mL streptomycin, and 100 mg/mL penicillin. CT-26 cells
were maintained in RPMI 1640 medium supplemented with
10% heat-inactivated FCS, 2 mM L-glutamine, 100 mg/mL
streptomycin, 100 and U/mL penicillin.
All cell culture reagents were obtained from Biological
Industries (Beit Haemek, Israel); tissue culture dishes and
enzyme-linked immunosorbent assay (ELISA) plates were
obtained from Greiner Labortecknik (Nürtingen, Germany)
and Nunc (Roskilde, Denmark).
In vivo gene therapy of established tumors
using AdCMVIL-12
Colon carcinoma was established by subcutaneous (s.c.) im-
plantation of CT-26 cells. An aliquot of 5 3 105 cells was
injected into the right hind flank of syngenic mice. After ;10
days, when the tumor reached 5 mm in diameter, different
doses of recombinant adenoviruses (AdCMVIL-12 at 108
plaque-forming units (PFU) and 109 PFU; AdCMVlacZ at 109
PFU) were injected i.t. in a volume of 50 mL diluted in saline.
Tumor growth was monitored two times per week by measur-
ing two perpendicular tumor diameters using calipers. Tumor
volume was calculated from the square of the longest diameter
(b) multiplied by a smaller diameter (a) of tumor according to
the following formula: V 5 a 3 b2. Animals with tumors that
were .1.5 cm in two perpendicular diameters or .2.0 cm in
one diameter were sacrificed for ethical reasons.
To treat bilateral tumors, 5 3 105 CT-26 cells were injected
s.c. into BALB/c mice in the right and left hind lank. When the
tumor on both sides reached 5 mm in diameter, the right tumor
was treated by an i.t. injection of 108 of AdCMVIL-12 (n 5 7)
or with the same dose of control vector AdCMVlacZ (n 5 4).
After treatment, the size of the tumors was measured as
described above.
To study protective immunity against rechallenge with tu-
moral cells, animals that were free of disease at 2 weeks, 2
months, and 4 months after complete regression of primary
tumors were rechallenged with 5 3 105 CT-26 cells at a distal
site. Age-matched naive animals received the same amount of
cells to serve as controls.
Cytokine production
To evaluate the production of IL-12 by CT-26 cells in vitro, we
infected 106 cells with AdCMVIL-12 or AdCMVlacZ at MOIs
(multiplicities of infection) of 1000, 100, 10, and 1. After 2
days, supernatants from infected cells were collected for the
determination of IL-12 concentration by ELISA. To estimate
the in vivo production of cytokines after treatment of the
tumors with adenoviruses, tumor tissue, blood samples, and
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spleen were collected at 1, 3, and 5 days posttreatment. Blood
was collected from the retro-orbital sinus. Tumor and spleen
were removed and frozen in liquid nitrogen. Frozen tissue was
homogenized in 0.5 mL of phosphate-buffered saline (PBS)
containing 100 mM phenylmethylsulfonyl fluoride and 10
mg/mL aprotinin (ICN Iberica, Barcelona, Spain). The homog-
enate was then sonicated for 10 seconds and cleared by
centrifugation in a microcentrifuge for 5 minutes at room
temperature. Samples were stored at 220°C.
ELISAs for IL-12 and IFN-g were performed as described
by Chensue et al.41 The 96-well microtiter plates were coated
overnight with anti-cytokine capture monoclonal antibody
(Ab) (PharMingen, San Diego, Calif) (4 mg/mL anti-IL-12 and
4 mg/mL anti-IFN-g) at 4°C. Plates were then washed twice
with PBS/Tween 20 solution, and nonspecific binding was
blocked using 10% FCS in PBS for 120 minutes at room
temperature. The blocking buffer was removed, and the wells
were washed four times. Samples were added and incubated
overnight at 4°C. The wells were washed six times, and a
biotinylated Ab was added (PharMingen) (20 ng/mL anti-IL-
12; 40 ng/mL anti-IFN-g) followed by a 30-minute incubation
at room temperature. Next, diluted avidin peroxidase (Boehr-
inger Mannheim, Mannheim, Germany) was added and incu-
bated at room temperature for 30 minutes. The plates were
washed eight times, and 100 mL of 2,29-azinobis(3-ethylbenzo-
thiazoline-6-sulfonic acid) (Boehringer Mannheim) was added
per well. Plates were read at an optical density of 405 nm. A
standard IL-12 and IFN-g curve containing known concentra-
tions of each cytokine was performed.
Cytotoxicity assay
Cytotoxicity assay was performed according to standard pro-
tocols.42 Viable splenocytes were isolated from the spleens of
animals that underwent the different forms of treatment. Red
blood cells were lysed by suspending the splenocytes in 5 mL of
0.83% ammonium chloride-potassium lysis buffer. In vitro
stimulation was performed for 5 days in 24-well plates, with
each well containing 8 3 106 splenocytes and 8 3 105 CT-26
cells treated previously with 150 mg/mL of mitomycin C for 30
minutes at 37°C. On day 5, fresh tumor cells were harvested
and 1 3 106/cells were labeled with 150 mCi of 51Cr for 1 hour.
After labeling, the cells were washed four times and adjusted
to 5 3 104/mL; next, 100 mL of this cell suspension was added
to 96-well flat-bottom plates and incubated with effector cells
for 5 hours at 37°C in different effector to target cell ratios. The
spontaneous and maximum release of 51Cr from tumor
cells was determined, with the latter using 0.8% Triton X-100.
After incubation, 51Cr radioactivity was measured in 50-mL
aliquots of the supernatants. Data represent the means of
triplicate cultures. The percentage of specific lysis was calcu-
lated using the following formula: ([cpm experimental 2 cpm
background])/[cpm maximum 2 cpm background]) 3 100.
Depletion of lymphocytes and tumor growth
The L3T4 CD41-specific rat anti-mouse hybridoma GK1–5
and the CD81-specific rat anti-mouse hybridoma H35.17.2
were used to obtain anti-CD41 and anti-CD81 Abs. Ascitic
fluid was obtained from pristane-primed nude mice injected
with 106 hybridoma cells. Abs were prepared by precipitation
with ammonium sulfate and dialyzed against PBS. The protein
concentration was assessed by optical density at 280 nm.
Tumor-bearing mice (three in each group) were depleted of
CD41 or CD81 cells by an intraperitoneal injection of 300 mg
of anti-CD41 or anti-CD81 Abs43 five times on days 23, 22,
21, 7, and 14. Animals received treatment by an i.t. injection
of AdCMVIL-12 on day 0. Tumor growth was assessed two
times per week.
Gene transfer efficiency to tumor nodules by in vivo
injection of adenovirus
Tumor-bearing mice were anesthetized with a mixture of
ketamine and xylacine. A total of 109 PFU of AdCMVlacZ in
50 mL of saline was injected i.t. Animals were sacrificed 2 days
later, and the tumors were excised, immediately embedded in
optimal cutting temperature compound (Tissue Tek, Zoeter-
woude, The Netherlands), and frozen in liquid nitrogen.
Sections of 6-mm thickness were fixed with glutaraldehyde
(0.5%) and stained with 5-bromo-4-chloro-3-indoyl-b-galacto-
sidase as described previously.44
RESULTS
Construction and characterization of AdCMVIl-12
Because IL-12 is heterodimer of p35 and p40 and
overexpression of p40 inhibits IL-12 activity, we con-
structed a bicistronic recombinant adenovirus vector
carrying p35 and p40 subunits of the IL-12 gene under
the control of the CMV promoter using an IRES
sequence from encephalomyocarditis virus, which allows
initiation of translation at downstream start codons (Fig
1A). This construction allows coordinated expression of
p35 and p40 of the IL-12 gene to obtain maximum
bioactivity of IL-12.
Cultured mouse colon cancer CT-26 cells were
infected with AdCMVIL-12 and control adenovirus
AdCMVlacZ at different MOIs (1000,100, 10, and 1).
The supernatant from infected cells was collected for the
measurement of IL-12 by specific ELISA for detection
of p70 heterodimer of IL-12. No IL-12 production was
found in AdCMVlacZ-infected CT-26 cells. In contrast,
as shown in Figure 1B, a dose-dependent production of
IL-12 was found in cells infected with AdCMVIL-12. As
observed, high levels of IL-12 are obtained at an MOI of
100, and a still higher production was achieved when the
MOI was increased to 1000.
In vivo gene therapy of established colon cancer
by AdCMVIL-12
To determine the antitumor activity of AdCMVIL-12,
we s.c. injected CT-26 murine colon cancer cells into
syngenic BALB/c mice. When tumor size attained 5 mm
in diameter, tumor-bearing animals were treated by an
i.t. injection of AdCMVIL-12 at 109 PFU (n 5 17) or 108
PFU (n 5 17), of control adenovirus AdCMVlacZ at 109
PFU (n 5 16), or of saline (n 5 14). After treatment, the
size of the tumors in animals treated with saline or with
AdCMVlacZ increased progressively. All animals from
these two control groups died, and mortality reached
100% at day 42 postinoculation (Fig 2, A and B).
In contrast, 13 of 17 animals treated with a high dose
of AdCMVIL-12 showed complete regression of the
tumor. Also, 13 of 17 animals treated with a low dose of
516 MAZZOLINI, QIAN, XIE, ET AL: GENE THERAPY FOR COLON CANCER
Cancer Gene Therapy, Vol 6, No 6, 1999
AdCMVIL-12 completely eliminated the neoplasm (Fig
2B). Tumors disappeared between days 7 and 10 after
vector administration. Histopathological study of the
regressing tumor nodules at 5 days after treatment
with AdCMVIL-12 showed extensive areas of necrosis
with polymorphs and some mononuclear cell infiltration
(Fig 3A). The animals treated with control vector
AdCMVlacZ had large nodules composed of undiffer-
entiated carcinoma cells without an associated inflam-
matory response (Fig 3B). Animals who eliminated the
tumor after AdCMVIL-12 treatment remained free of
tumor and survived until the time of writing this manu-
script (200 days after administration of the vector). Of
the remaining eight animals, the tumor was quiescent for
a period of 2–5 weeks in six cases; in the other two cases,
no apparent effect of the treatment on tumor growth was
observed. These results indicate that AdCMVIL-12 even
at a low dose (108 PFU) has a strong antitumoral effect
on established tumors. We also studied gene transfer
efficiency in this animal model by i.t. injection of AdC-
MVlacZ. We found that ;10% of tumor cells could be
effectively transduced after an i.t. injection of 108 PFU
of the vector (Fig 3C). It seems that this proportion
of transduced cells is enough for the production of IL-12
in sufficient amounts to induce a strong antitumoral
effect.
Local and systemic expression of IL-12 and IFN-g after
i.t. injection of AdCMVIL-12
IL-12 is a strong inducer of IFN-g.15,45 To analyze the i.t.
and systemic levels of IL-12 and IFN-g after the treat-
ment of tumors with AdCMVIL-12, we measured the
concentrations of these cytokines in tumor homo-
genates, sera, and spleens at different time intervals
in animals that had been subjected to i.t. injections
of AdCMVIL-12 at 108 PFU, control adenovirus
AdCMVlacZ, or saline. Table 1 shows that a substantial
production of both IL-12 and IFN-g takes place in
tumors treated with AdCMVIL-12, whereas insignificant
or undetectable levels of these cytokines were found in
tumors treated with the control adenovirus or saline.
Serum or spleen concentrations of IL-12 and IFN-g
were under the detection limit of the ELISA in all cases
(,0.03 ng/mL). These results indicate that our vector is
able to induce high i.t. levels of both IL-12 and IFN-g
without increasing systemic cytokine concentrations.
Figure 1. Construction and characterization of AdCMVIL-12. A:
Schematic representation of the bicistronic recombinant adenovirus
AdCMVIL-12. This vector carries p35 and p40 subunits of the IL-12
gene linked with IRES under the control of the CMV promoter. This
expression cassette replaces the E1 region of the Ad5 genome. B:
IL-12 production in CT-26 cells after infection with AdCMVIL-12.
CT-26 cells were plated in six-well plates and infected with
AdCMVIL-12 or AdCMVlacZ at different MOIs. After 48 hours,
supernatant was collected for the measurement of IL-12 by ELISA.
Data represent the mean of two experiments.
Figure 2. In vivo gene therapy of established colon cancer im-
planted s.c. Mice with s.c. established colon cancer were treated
with either AdCMVIL-12 at 109 PFU (n 5 17), AdCMVIL-12 at 108
PFU (n 5 17), control adenovirus AdCMVlacZ at 109 PFU (n 5 16),
or saline (n 5 14). The size of the tumor was measured, and deaths
of animals were documented. A: Size of tumor after treatment with
AdCMVIL-12. B: Long-term survival of animals after treatment with
AdCMVIL-12.
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Involvement of T-cell subtypes in the regression of
colon cancer by AdCMVIL-12
Because IL-12 is very efficient at activating T-cell immu-
nity, we investigated the role of CD41 and CD81 T cells
in mediating the antitumoral effect of AdCMVIL-12. To
this aim, in vivo depletion of CD41 or CD81 cells was
carried out by an intraperitoneal injection of anti-CD4
or anti-CD8 Abs before treatment of the tumors with
AdCMVIL-12. The efficiency of CD41 and CD81 de-
pletion was .99% (data not shown) as measured by flow
cytometry. As shown in Figure 4, the tumor growth rate
in CD81-depleted mice that had been treated with an i.t.
injection of AdCMVIL-12 was similar to that observed
in untreated controls. In contrast, tumor growth in
CD41-depleted mice that had received i.t. injections of
AdCMVIL-12 was still substantially inhibited compared
with untreated animals. In fact, 66% of CD41-depleted
mice treated with AdCMVIL-12 showed complete tu-
mor regression. Thus, our results point to a critical role
of CD81 T cells in mediating the anti-oncogenic effect
resulting from an i.t. injection of AdCMVIL-12.
AdCMVIL-12 elicits antitumoral cytotoxic
T-lymphocyte (CTL) response
Having shown that CD81 T cells are involved in tumor
regression in animals subjected to local treatment with
AdCMVIL-12, we further investigated whether this
therapy was able to induce a CTL response against colon
cancer cells. At 15 days after treatment with 108 PFU of
AdCMVIL-12, control adenovirus AdCMVlacZ, or sa-
line, spleens from tumor-bearing animals were obtained
and were used to analyze specific CTL activity against
CT-26 cells. As shown in Table 2, there was no signifi-
cant CTL activity against CT-26 cells in splenocytes from
saline- and AdCMVlacZ-treated animals. In contrast, a
high CTL lytic activity against CT-26 cells was detected
in splenocytes from animals treated with AdCMVIL-12.
A high level of CTL activity was also observed in lymph
nodes from AdCMVIL-12-treated animals, but not in
lymph nodes from control animals (data not shown).
These results indicate that local expression of IL-12 in
tumor nodules induces a potent systemic CTL activity
against colon cancer cells.
Local AdCMVIL-12 gene therapy of colon cancer
induces distant antitumoral effects
Because a systemic antitumoral CTL response was elic-
ited by local administration of AdCMVIL-12, we evalu-
ated whether injection of AdCMVIL-12 into a tumor
nodule had any effect on distant tumoral lesions. To this
aim, we used an animal model with implanted bilateral
tumor nodules in which only one of the tumors was
treated. Thus, mice were injected s.c. with CT-26 cells
bilaterally and, when tumor nodules were 5 mm in
diameter on both sides, tumors on the right side were
treated with an i.t. injection of 108 PFU of AdCMVIL-12
(n 5 7) or AdCMVlacZ (n 5 4). All animals that were
treated with control AdCMVlacZ showed progressive
tumor growth on both sides and finally died. However,
treatment with AdCMVIL-12 induced complete regres-
sion of the tumor on the right side (treated tumor) in five
of seven animals (Fig 5A); more importantly, this treat-
ment also induced complete regression of the tumor on
the left side (untreated tumor) in three of seven animals
and partial left tumor regression in the rest of the
animals (Fig 5B). These data suggest that a local i.t.
injection of AdCMVIL-12 can eradicate treated tumors
and activate a specific CTL response that is able to
control tumor growth at distant sites.
Figure 3. Histological analysis of colon cancer after treatment with
different vectors. Animals with established tumors were treated by
an i.t. injection of AdCMVIL-12 at 108 PFU or with AdCMVlacZ at
same dose. After 5 days, tumors were collected for hematoxylin and
eosin (H&E) staining. A: A tumor from an AdCMVIL-12-treated
animal. It shows extensive necrotic areas, lymphocyte infiltration
(thick arrows), and few remaining tumor cells (thin arrows) (H&E,
3400). B: A tumor from an AdCMVlacZ-treated animal. It shows an
undifferentiated carcinoma with no apparent inflammatory compo-
nent (H&E, 3400). C: Gene transfer efficiency in a tumor after i.t.
injection of adenoviral vector. At 2 days after i.t. administration of
AdCMVlacZ-12 at 108 PFU, tumors were collected for 5-bromo-4-
chloro-3-indoyl-b-galactosidase staining. The arrow shows adeno-
virus-transduced cells (3200).
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Long-term antitumor immunity induced by i.t.
injection of AdCMVIL-12
To determine whether local treatment of tumor nodules
with AdCMVIL-12 can induce lasting immunological
memory, we rechallenged animals that were free of
tumors after AdCMVIL-12 treatment with a new s.c.
administration of CT-26 cells at 2 weeks, 2 months, and
4 months after complete regression of primary tumors.
Figure 6A shows that when animals were rechallenged at
day 14 after tumor disappearance, all animals (10 of 10)
rejected the s.c. implantation of 5 3 105 parental CT-26
cells. When animals were rechallenged with parental
CT-26 cells at 2 and 4 months after the disappearance of
the initial tumor, 1 of 11 animals and 0 of 6 animals
developed tumors, respectively (Fig 6, B and C). The
protection was observed in 96.4% of all animals that
eliminated the initial neoplasm after AdCMVIL-12 ther-
apy. By contrast, in the control group, 22 of 22 mice
developed a s.c. tumor after inoculation of CT-26 cells.
These data indicate that in vivo gene therapy using
AdCMVIL-12 vector can induce long-term protection
against tumor recurrence.
DISCUSSION
As in other tumors, the progression of colon cancer with
local growth, invasion of regional lymph nodes, and
distant metastasis in the presence of an intact immune
system indicates that malignant cells have developed
highly efficient mechanisms to evade immunosurveil-
lance. In fact, many investigators have observed im-
proved survival in cases with an apparent immunological
response in regional lymph nodes and an even greater
increase in survival when this feature was present with a
local inflammatory reaction to the primary tumor.46,47
IL-12 is a key factor in the orchestration of cell
immunity, promoting T helper type 1 responses.10 This
cytokine has been shown to be very effective in stimu-
lating host antitumoral responses in different animal
models of solid tumors and also in human clinical
trials7,9,17–21,23,24. However serious toxic side effects pro-
hibit the use of IL-12 by the systemic route.23,24 Thus,
procedures allowing local production of the cytokine
within the tumor mass to activate the immunological
reaction against the neoplasm could lead to tumor
regression without accompanying toxicities.
Local production of IL-12 can be achieved by gene
transfer methodologies. Gene gun, vaccinia virus, ade-
novirus, and direct injection of plasmid have been used
to transfer IL-12 genes to the tumor that demonstrate
antitumoral effects in various solid neoplasms in differ-
ent animal models.29–36 With respect metastatic colon
cancer, prolonged survival was reported when adenovi-
rus encoding IL-12 was administered i.t. to the poorly
immunogenic cell line MCA-26, although mechanisms
of the antitumoral effect were not investigated.33
In the present work, we have used an adenovirus
expressing high levels of bioactive IL-12 in a murine
model of colon cancer using the CT-26 cell line. This cell
line is poorly immunogenic and does not induce signif-
icant cytotoxic T-cell responses by itself.48,49 An adeno-
viral vector was selected because it does not integrate
into the cell genome and because it can transduce
dividing and nondividing cells in vivo with great effi-
ciency; in addition, although it allows a strong local
expression of IL-12, the expression is transient and there
Figure 4. Involvement of T-cell subtypes in the anti-oncogenic effect
of AdCMVIL-12. Depletion of CD41 or CD81 T cells was carried out
by injection of anti-CD41 or anti-CD81 Ab into tumor-bearing
animals before and after local treatment of tumors with AdCMVIL-
12. Depletion of CD81 T cells abrogates the antitumoral effect of the
treatment (tumor growth rate is similar to that of untreated controls).
Depletion of CD41 T cells does not substantially affect the antitu-
moral effect of the treatment; in these animals, the tumor growth
rate is still markedly inhibited compared with untreated controls.
Table 1. IL-12 and IFN-g Cytokine Production After I.t.
Injection of AdCMVIL-12
Cytokines Groups
Days posttreatment
1 3 5
IL-12 AdCMVIL-12 1.1 (0.036)* 5.7 (0.14) ND†
AdlacZ 0.03 (0.011) 0.04 (0.02) ND
Saline 0.15 (0.04) 0.24 (0.032) ND
IFN-g AdCMVIL-12 ND 0.05 (0.05) 0.01 (0.16)
AdCMVlacZ ND ,0.03‡ ,0.03
Saline ND ,0.03 ,0.03
*Numbers represent the mean of three animals per group
(nanograms per milligram of tumor tissue) for each cytokine. SD is
expressed in parenthesis.
†ND, not determined.
‡Under the level of detection.
Table 2. CTL Activity in Splenocytes After an I.t.
Injection of AdCMVIL-12
Groups
Cytotoxic index (%)
33:1* 11:1
AdCMVIL-12 42.3† 22.1
AdCMVlacZ 20.11 20.4
Saline 20.7 20.05
Control 0.73 0.12
*Effector to target cell ratios.
†Mean values for three animals per group.
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is not risk of sustained stimulation of the immune system
as can occur with retroviruses and other integrating
vectors. AdCMVIL-12 was constructed to permit the
coordinated production of p40 and p35 to obtain the
maximum IL-12 bioactivity, because an excess of p40
could lead to the formation of p40 homodimers, which
can combine with IL-12 receptor to reduce the antitu-
moral effect of the cytokine.35
In the present study, we show that injection of
AdCMVIL-12 directly into the neoplastic nodule is
followed by local production of high levels of IL-12 and
IFN-g, with IL-12 values near 6 ng/mg of tumor at day 3
postinoculation and IFN-g values near 0.1 ng/mg of
tumor at day 5. The induction of IFN-g after tumor
transduction with AdCMVIL-12 indicates that the IL-12
produced by tumor cells is biologically active and exerts
its characteristic immunoregulatory functions. Impor-
tantly, systemic levels of these cytokines were undetect-
able, a finding that correlates with the absence of toxic
effects in animals receiving the treatment.
Between days 7 and 10 after AdCMVIL-12 inocula-
tion, the tumor regressed in 94% of animals; complete
disappearance of the lesion was seen in 76% of treated
mice. Results were comparable with a low (108 PFU) or
high (109 PFU) dose of the vector, indicating a wide
therapeutic window for this form of therapy. Regression
of the tumor was associated with prolonged survival;
those animals that responded with complete tumor
regression remained alive up to the moment of writing
this manuscript (200 days after vector administration).
In our system, tumor rejection appears to be mediated
mainly by CD81 cells, because depletion of this lympho-
Figure 5. Local AdCMVIL-12 gene therapy of one tumor (right side)
induces a distant antitumoral effect on the contralateral tumor (left
side) in animals with bilateral established tumors. A: Size of the
tumor on the right side (treated tumor) in animals that received
an i.t. injection of AdCMVIL-12 (108 PFU) or control adenovirus
AdCMVlacZ (108 PFU). B: Size of the tumor on the left side
(untreated tumor) in animals in which the right side tumor was
treated with AdCMVIL-12 (1 3 108 PFU) or control adenovirus
AdCMVlacZ (1 3 108 PFU).
Figure 6. Long-term protection against parental colon cancer cell
rechallenge at distant sites. CT-26 cells (5 3 105 cells) were
inoculated s.c. in the flanks of animals that had been cured after
treatment of established tumor with AdCMVIL-12 and also in the
flanks of age- and sex-matched naive animals. Deaths of animals
were documented, and results were expressed as the percentage of
animal survival. A: Animals inoculated with CT-26 cells 14 days after
complete regression of the initial tumor (n 5 10). B: Animals
inoculated with CT-26 cells 2 months after complete regression of
the initial tumor (n 5 11). C: Animals inoculated with CT-26 cells 4
months after complete regression of the initial tumor (n 5 6).
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cyte subpopulation, but not of CD41 cells, largely abro-
gated the inhibition of tumor growth caused by AdCM-
VIL-12 treatment. This finding, together with the
emergence of a potent CTL response against tumor cells
in animals treated with AdCMVIL-12, indicates that
immune rejection is the basic mechanism of the antitu-
moral effect of the therapy. Other mechanisms, includ-
ing anti-angiogenic effects of IL-12, IFN-g, or IFN-g-
induced factors,50–52 could also contribute to the anti-
oncogenic potential of the procedure.
Recently, Toda et al36 have shown that i.t. inoculation
of a combination of replication-competent herpes sim-
plex virus (HSV) plus defective HSV vector encoding
IL-12 in a murine model of colon cancer induced
cytotoxic T-cell responses and increased survival. How-
ever, the mortality of treated animals reached 100% at
week 7 after therapy. In this study, i.t. IL-12 levels were
low and ;50–100 pg/tumor was produced in vector-
inoculated tumors at 5 days postinoculation.36 It seems
possible that the limited antitumoral effect could be due
to low in vivo transduction efficiency using HSV vectors.
In our study, as in the report by Toda et al,36 the
generation of CTL responses against tumor cells could
explain the important inhibition of tumor growth ob-
served in lesions distant to the nodule treated with
AdCMVIL-12. The protection obtained by activation of
antitumoral immunity was also evident in experiments
showing that animals that eliminated the tumor after i.t.
administration of AdCMVIL-12 resisted a new chal-
lenge with tumor cells administered up to 4 months after
the disappearance of the initial tumor.
These important properties of in vivo tumor transduc-
tion with IL-12 are relevant when considering potential
applications in humans. As mentioned, the presence of
an immune reaction against primary colon cancer or
lymph node metastasis in the surgical specimen has been
recognized as a factor improving prognosis.46,47 How-
ever, circulating tumoral cells have been found in the
portal vein at the time of surgery, a finding which may be
related to the occurrence of metachronous metastasis.53
Thus, it seems possible that transduction of the primary
tumor with vectors expressing IL-12 at endoscopy, be-
fore the intervention, may favor the prognosis and
reduce recurrences after surgery by stimulating specific
CTL responses that could eliminate small metastatic
foci. In addition, this therapy could also be of value in
advanced metastatic disease, a situation for which there
is no effective treatment available at present.
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